144 related articles for article (PubMed ID: 10714061)
1. [Bone scintigraphy in metastatic bone disease].
Itoh K
Kaku Igaku; 2000 Jan; 37(1):1-5. PubMed ID: 10714061
[TBL] [Abstract][Full Text] [Related]
2. Bone scintigraphy in the evaluation of cancer.
Gupta V
Kathmandu Univ Med J (KUMJ); 2005; 3(3):243-8. PubMed ID: 18650585
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of osseous metastasis in bone scintigraphy.
Davila D; Antoniou A; Chaudhry MA
Semin Nucl Med; 2015 Jan; 45(1):3-15. PubMed ID: 25475375
[TBL] [Abstract][Full Text] [Related]
4. Tc-99m PMT whole-body scintigraphy for evaluated of therapeutic effect and for monitoring bone metastasis in a patient with hepatocellular carcinoma.
Sueyoshi K; Narabayashi I; Doi K; Takahashi M; Komori T; Tatsu Y; Tatsumi T; Utunomiya K; Uesugi Y; Adachi I; Shimizu T
Clin Nucl Med; 2000 Dec; 25(12):1000-3. PubMed ID: 11129132
[TBL] [Abstract][Full Text] [Related]
5. [Clinical usefulness of 201Tl-chloride scintigraphy for the evaluation of metastatic bone lesions].
Fukui A; Kawamura M; Kataoka M; Fujii T; Yamamoto K; Yoshioka S; Ikezoe J
Nihon Igaku Hoshasen Gakkai Zasshi; 1998 Jan; 58(1):25-33. PubMed ID: 9493430
[TBL] [Abstract][Full Text] [Related]
6. [Assessment of solitary hot spots of bone scintigraphy in patients with extraskeletal malignancies].
Tomoda Y; Ishino Y; Nakata H
Kaku Igaku; 2001 Nov; 38(6):721-6. PubMed ID: 11806083
[TBL] [Abstract][Full Text] [Related]
7. [[Advantages and limitations of whole-body bone marrow MRI using Turbo-STIR sequences in comparison to planar bone scans] ].
Tausig A; Manthey N; Berger F; Sommer H; Pfluger T; Hahn K
Nuklearmedizin; 2000 Sep; 39(6):174-9. PubMed ID: 11057409
[TBL] [Abstract][Full Text] [Related]
8. Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer.
Hahn S; Heusner T; Kümmel S; Köninger A; Nagarajah J; Müller S; Boy C; Forsting M; Bockisch A; Antoch G; Stahl A
Acta Radiol; 2011 Nov; 52(9):1009-14. PubMed ID: 21969709
[TBL] [Abstract][Full Text] [Related]
9. Comparison of whole-body MRI and bone scintigraphy in the detection of bone metastases in renal cancer.
Sohaib SA; Cook G; Allen SD; Hughes M; Eisen T; Gore M
Br J Radiol; 2009 Aug; 82(980):632-9. PubMed ID: 19221182
[TBL] [Abstract][Full Text] [Related]
10. Whole-body iodine-131 metaiodobenzylguanidine imaging for detection of bone metastases in patients with paraganglioma: comparison with bone scintigraphy.
Inoue T; Yoshinaga K; Morita K; Shiga T; Kanegae K; Hirata K; Okamoto S; Tamaki N
Ann Nucl Med; 2007 Jul; 21(5):307-10. PubMed ID: 17634850
[TBL] [Abstract][Full Text] [Related]
11. [131I-MIBG scintigraphy for the detection of metastatic lesions from malignant pheochromocytoma--comparison of 131I-MIBG scintigraphy with 99mTc-MDP bone scintigraphy in detecting bone metastases].
Ozawa N; Imaeda T; Seki M; Koike S
Kaku Igaku; 1988 Jan; 25(1):97-103. PubMed ID: 3373813
[No Abstract] [Full Text] [Related]
12. Spectral parametric segmentation of contrast-enhanced dual-energy CT to detect bone metastasis: feasibility sensitivity study using whole-body bone scintigraphy.
Lee YH; Kim S; Lim D; Suh JS; Song HT
Acta Radiol; 2015 Apr; 56(4):458-64. PubMed ID: 24714734
[TBL] [Abstract][Full Text] [Related]
13. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
14. The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis.
Tsai SH; Chen CY; Ku CH; Janckila AJ; Yam LT; Yu JC; Chuang KW; Chao TY
Mayo Clin Proc; 2007 Aug; 82(8):917-26. PubMed ID: 17673059
[TBL] [Abstract][Full Text] [Related]
15. Skeletal scintigraphy in breast cancer management.
Bares R
Q J Nucl Med; 1998 Mar; 42(1):43-8. PubMed ID: 9646644
[TBL] [Abstract][Full Text] [Related]
16. [Is bone scintigraphy still required for screening metastatic bone disease?].
Munz DL
Nuklearmedizin; 1994 Aug; 33(4):5-6, 9-10. PubMed ID: 7971293
[No Abstract] [Full Text] [Related]
17. [Clinical efficacy of bone scintigraphy for metastatic bone tumors].
Nakajima T; Sugiyama S; Yamakawa M
Rinsho Hoshasen; 1983 May; 28(5):579-83. PubMed ID: 6887613
[No Abstract] [Full Text] [Related]
18. Can bone scintigraphy detect additional metastatic sites unrevealed by CT in patients with recurrent ovarian carcinoma?
Uysal U; Kostakoğlu L; Elahi N; Aydingöz U; Firat D; Bekdik CF
Radiat Med; 1997; 15(1):55-8. PubMed ID: 9134586
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of whole-body MR imaging and bone scintigraphy in the detection of bone metastases from breast cancer].
Tamada T; Nagai K; Iizuka M; Imai S; Kajihara Y; Yamamoto S; Kurebayashi J; Shimozuma K; Sonoo H; Fukunaga M
Nihon Igaku Hoshasen Gakkai Zasshi; 2000 Apr; 60(5):249-54. PubMed ID: 10824532
[TBL] [Abstract][Full Text] [Related]
20. Comparison between whole-body positron emission tomography and bone scintigraphy in evaluating bony metastases of esophageal carcinomas.
Kato H; Miyazaki T; Nakajima M; Takita J; Kimura H; Faried A; Sohda M; Fukai Y; Masuda N; Fukuchi M; Manda R; Ojima H; Tsukada K; Kuwano H; Oriuchi N; Endo K
Anticancer Res; 2005; 25(6C):4439-44. PubMed ID: 16334123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
